Nov 3, 2017 by Brian Orelli, PhDWhy Emergent BioSolutions Inc. Jumped Higher TodayThere's more to come from the biodefense specialist after a solid third quarter.
Nov 2, 2017 by Brian Orelli, PhDIDEXX Laboratories, Inc. Puts Long-Term Profits Ahead of Short-Term RevenueInstrument placements gave birth to sales of high-margin consumables.
Nov 1, 2017 by Brian Orelli, PhDWhy ImmunoGen, Inc. Got Burned into ASH TodayData for the upcoming American Society of Hematology meeting failed to impress investors.
Nov 1, 2017 by Brian Orelli, PhDBioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth GoalThe biotech keeps plugging along.
Nov 1, 2017 by Brian Orelli, PhDSeattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to ComeA solid third quarter from the biotech, but all eyes are on expanding the use of Adcetris.
Nov 1, 2017 by Brian Orelli, PhDWhy bluebird bio Inc. Jumped Higher TodayAbstracts for the American Society of Hematology meeting are out!
Oct 31, 2017 by Brian Orelli, PhDWhy Endo International plc Jumped and Then Faded -- TwiceThe drugmaker can't sustain a rally despite solid third quarter preliminary results.
Oct 30, 2017 by Brian Orelli, PhDWhy Adamas Pharmaceuticals Inc. Jumped Higher TodaySteven Cohen's Point72 Asset Management disclosed a big stake in the biotech, but be careful following the guru.
Oct 30, 2017 by Brian Orelli, PhDCelgene Corporation Has "Optionality and Opportunity"It was a disappointing third quarter for the biotech, but the drugmaker still has lots of potential.
Oct 30, 2017 by Brian Orelli, PhDWhy Advanced Accelerator Applications SA Acquired a Higher Price TodayThe French biotech is being acquired by Novarits.
Oct 27, 2017 by Brian Orelli, PhDVertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the PipelineBoth are important for the future of the biotech.
Oct 26, 2017 by Brian Orelli, PhDOh Baby! Natus Medical Inc. Beats and Raises GuidanceAfter a rough start to the year, the newborn care, audiology, and neurology company is back on track.
Oct 26, 2017 by Brian Orelli, PhDWhy Celgene Corporation Tumbled TodayThe biotech revised long-term guidance lower, but the growth prospects still look promising.
Oct 25, 2017 by Brian Orelli, PhDBiogen Inc Content With "Resilience" of Its Multiple Sclerosis FranchiseFortunately, the biotech has a new spinal muscular atrophy drug that's boosting sales.
Oct 23, 2017 by Brian Orelli, PhDWhy DBV Technologies SA Plummeted and Aimmune Therapeutics Inc Skyrocketed TodayOne biotech's phase 3 failure benefits its competitor.
Oct 20, 2017 by Brian Orelli, PhDWhy Celgene Corporation Dropped TodayA phase 3 failure sent shares down.
Oct 16, 2017 by Brian Orelli, PhDWhy Exelixis, Inc. Rose Higher TodayPositive phase 3 data for Cabometyx in liver cancer sends shares of the biotech higher.
Oct 13, 2017 by Brian Orelli, PhDWhy Antares Pharma Inc Plummeted TodayAn FDA rejection is coming for the drugmaker's testosterone replacement therapy Xyosted.
Oct 12, 2017 by Brian Orelli, PhDWhy Ardelyx Inc Skyrocketed Higher TodayPositive phase 3 data for the biotech's irritable bowel syndrome drug, tenapanor, sends shares higher.
Oct 12, 2017 by Brian Orelli, PhDWhy AcelRx Pharmaceuticals Inc Got Cut in Half TodayAn FDA rejection sends shares of the drugmaker lower.
